Transparency

Every source we watch

There is no mystery feed. Below is the complete list of 10 sources the radar polls, what we take from each, and the exact endpoint we read — so you can open the same data we do and check any item on the feed against its primary source. Every source is a government publication or a licensed legislative dataset. None of it is scraped from competitors, purchased from a broker, or generated.

• LegiScan (state legislation)

  LegiScankeyed API

  Introduced and amended bill text on GLP-1/peptide compounding, scope of practice, and aesthetic practice regulation, diffed by change hash so an amendment reads as a change, not a duplicate.

  Coverage

  All 50 state legislatures + the District of Columbia

  Appears on

  /feed · /states

  Endpoint

  https://api.legiscan.com/

  Terms

  CC BY 4.0 — attribution required

  browse this source ↗

• FDA / Federal Register (compounding)

  U.S. Federal Register

  FDA rules, notices, and guidance mentioning 503A/503B compounding, bulk drug substances, and GLP-1s — the federal half of the compounding picture.

  Coverage

  Every FDA document published in the Federal Register

  Appears on

  /feed

  Endpoint

  https://www.federalregister.gov/api/v1/documents.json

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Drug Shortages (GLP-1)

  U.S. FDA (openFDA)

  Shortage status for GLP-1 drugs. Shortage status is the switch that governs whether a drug may be compounded at all, so a status flip is a legality change, not a supply note.

  Coverage

  GLP-1 drugs on the FDA shortage list

  Appears on

  /feed · /tracker

  Endpoint

  https://api.fda.gov/drug/shortages.json

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Drug Enforcement / Recalls

  U.S. FDA (openFDA)

  Drug recalls and enforcement reports covering GLP-1 and compounded injectable products, with the recall class attached.

  Coverage

  openFDA drug enforcement reports, filtered to compounding/aesthetics products

  Appears on

  /feed · /impact

  Endpoint

  https://api.fda.gov/drug/enforcement.json

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Device Enforcement / Recalls

  U.S. FDA (openFDA)

  Device recalls narrowed to aesthetic equipment — lasers, IPL, RF microneedling, and cryolipolysis.

  Coverage

  openFDA device enforcement reports, filtered to aesthetic devices

  Appears on

  /feed · /impact

  Endpoint

  https://api.fda.gov/device/enforcement.json

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Warning Letters

  U.S. FDA (Data Dashboard)keyed API

  Warning Letters issued to CDER/CDRH firms on the compounding and aesthetics allowlist — the letter that lands on a supplier before a recall does.

  Coverage

  FDA compliance actions, filtered to compounders and aesthetic-product firms

  Appears on

  /feed · /impact

  Endpoint

  https://api-datadashboard.fda.gov/v1/compliance_actions

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Import Refusals (gray-market injectables)

  U.S. FDA (Data Dashboard)keyed API

  Injectables refused entry at the border — semaglutide, botulinum toxin, dermal filler, lidocaine. Evidence of a gray market, per shipment.

  Coverage

  FDA import refusals, filtered to injectable products

  Appears on

  /feed (background — see /methodology)

  Endpoint

  https://api-datadashboard.fda.gov/v1/import_refusals

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FDA Drug/Biologic Inspection Citations (503B)

  U.S. FDA (Data Dashboard)keyed API

  Inspection citations at drug and biologic facilities, grouped per inspection and narrowed to compounder and sterile-injectable signals.

  Coverage

  FDA inspection citations at Drugs/Biologics facilities

  Appears on

  /feed (background — see /methodology)

  Endpoint

  https://api-datadashboard.fda.gov/v1/inspections_citations

  Terms

  U.S. Government work — public domain

  browse this source ↗

• FTC Enforcement / Consumer Protection

  U.S. FTC

  FTC actions on deceptive weight-loss, compounded-GLP-1, and supplement marketing — the advertising side of the risk, which no FDA feed carries.

  Coverage

  FTC press releases, filtered to weight-loss and health-claim marketing actions

  Appears on

  /feed · /impact

  Endpoint

  https://www.ftc.gov/feeds/press-release.xml

  Terms

  U.S. Government work — public domain

  browse this source ↗

• Substance tracker (peptide / PCAC standings)

  U.S. Federal Register

  Compounding, PCAC, and bulk-substance documents resolved into a per-substance status history — so the tracker can say when a standing last changed, and on which document.

  Coverage

  Federal Register compounding/PCAC/bulk-substance documents

  Appears on

  /tracker

  Endpoint

  https://www.federalregister.gov/api/v1/documents.json

  Terms

  U.S. Government work — public domain

  browse this source ↗